Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Astrid Bosma

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 10, 2008
No effect of red clover-derived isoflavone intervention on the insulin-like growth factor system in women at increased risk of colorectal cancerAlina Vrieling, Matti A Rookus, Ellen Kampman, et al.
NPJ Breast Cancer|June 8, 2022
Allelic expression imbalance of PIK3CA mutations is frequent in breast cancer and prognostically significantLizelle Correia, Ramiro Magno, Joana M Xavier, et al.
Cell|May 15, 2018
An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic PotentialLiqin Wang, Rodrigo Leite de Oliveira, Sanne Huijberts, et al.
Molecular Oncology|January 18, 2023
Rational combination of SHP2 and mTOR inhibition for the treatment of hepatocellular carcinomaAntonio Mulero-Sánchez, Christel F A Ramirez, Aimée du Chatinier, et al.
Breast Cancer Research : BCR|August 31, 2017
The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant settingTesa M Severson, Denise M Wolf, Christina Yau, et al.
Molecular Oncology|May 26, 2015
BRCA1-like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potentialTesa M Severson, Justine Peeters, Ian Majewski, et al.
Cell Reports. Medicine|November 17, 2022
Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pancreatic cancerKatrin J Frank, Antonio Mulero-Sánchez, Alexandra Berninger, et al.
The Journal of Pathology|May 11, 2013
Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencingIan J Majewski, Lorenza Mittempergher, Nadia M Davidson, et al.
Nature|July 22, 2021
EGFR activation limits the response of liver cancer to lenvatinibHaojie Jin, Yaoping Shi, Yuanyuan Lv, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 10, 2008
No effect of red clover-derived isoflavone intervention on the insulin-like growth factor system in women at increased risk of colorectal cancerAlina Vrieling, Matti A Rookus, Ellen Kampman, et al.
NPJ Breast Cancer|June 8, 2022
Allelic expression imbalance of PIK3CA mutations is frequent in breast cancer and prognostically significantLizelle Correia, Ramiro Magno, Joana M Xavier, et al.
Cell|May 15, 2018
An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic PotentialLiqin Wang, Rodrigo Leite de Oliveira, Sanne Huijberts, et al.
Molecular Oncology|January 18, 2023
Rational combination of SHP2 and mTOR inhibition for the treatment of hepatocellular carcinomaAntonio Mulero-Sánchez, Christel F A Ramirez, Aimée du Chatinier, et al.
Breast Cancer Research : BCR|August 31, 2017
The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant settingTesa M Severson, Denise M Wolf, Christina Yau, et al.
Molecular Oncology|May 26, 2015
BRCA1-like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potentialTesa M Severson, Justine Peeters, Ian Majewski, et al.
Cell Reports. Medicine|November 17, 2022
Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pancreatic cancerKatrin J Frank, Antonio Mulero-Sánchez, Alexandra Berninger, et al.
The Journal of Pathology|May 11, 2013
Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencingIan J Majewski, Lorenza Mittempergher, Nadia M Davidson, et al.
Nature|July 22, 2021
EGFR activation limits the response of liver cancer to lenvatinibHaojie Jin, Yaoping Shi, Yuanyuan Lv, et al.
Pageof 2